What next for botulism vaccine development?

@article{Webb2013WhatNF,
  title={What next for botulism vaccine development?},
  author={Robert P Webb and Leonard A. Smith},
  journal={Expert Review of Vaccines},
  year={2013},
  volume={12},
  pages={481 - 492}
}
Botulism is a severe neuroparalytic disease caused by the toxins produced from several Clostridium species. Botulinum neurotoxins (BoNTs) cause flaccid paralysis by inducing a blockade at voluntary motor and autonomic cholinergic junctions that, if not treated, can be fatal. Vaccination to elicit protective circulating antibodies that bind, neutralize and clear toxins before they can be internalized and affect cholinergic neurons remains the most effective form of protection against BoNT. A… Expand
Vaccine delivery strategies against botulism
TLDR
This chapter is focused on reviewing new vaccine and immunotherapeutic strategies against botulism, including vaccine vector updates, immune sequence optimization, and recombinant antibodies. Expand
Vaccines against Botulism
TLDR
The different vaccines being developed to replace the discontinued toxoid vaccine are reviewed, which include DNA-based, viral vector- based, and recombinant protein-based vaccines. Expand
Production of recombinant botulism antigens: a review of expression systems.
TLDR
The present review describes the problematic of botulism and discusses the main advances for the viable production of vaccines for both human and veterinary medicine using recombinant antigens. Expand
Potency and stability of a trivalent, catalytically inactive vaccine against botulinum neurotoxin serotypes C, E and F (triCEF).
TLDR
Data is presented that a trivalent formulation of ciBoNT/C1,/E1 and/F1 (triCEF) maintains potency against both monovalent and polyvalent toxin challenges when stored as an adjuvanted vaccine at 4-8 °C for up to 2 years. Expand
Recombinant Botulinum Neurotoxin Hc Subunit (BoNT Hc) and Catalytically Inactive Clostridium botulinum Holoproteins (ciBoNT HPs) as Vaccine Candidates for the Prevention of Botulism
TLDR
The results suggest the ciBoNT HP vaccines exhibit superior potency after single vaccinations but multiple vaccinations with BoNT/Hc antigens resulted in increased survival rates at the toxin challenge levels used. Expand
Induction of protective neutralizing antibody responses against botulinum neurotoxin serotype C using plasmid carried by PLGA nanoparticles
TLDR
It was shown that immunization with plasmid DNA that encodes the 50 KDa C-terminal fragment of the heavy chain of BoNT serotypes that cause human botulism and is carried by cationic poly (lactic-co-glycolic) acid (PLGA) nanoparticles induces stronger BoNT/C-specific antibody responses, as compared to Immunization with the plasmids alone. Expand
Production and characterization of a neutralizing antibody against botulinum neurotoxin A.
TLDR
The results indicated that ML06 served as a good candidate for further development of immune therapeutics for BoNT/A, and can neutralize the toxin of Bo NT/A effectively both in vitro and in vivo, in a dose-dependent manner. Expand
Enhancing toxin-based vaccines against botulism.
TLDR
M-Bo NT/A1W, with defects in multiple toxin functions, elicits a potent immune response to BoNT/A challenge as a vaccine strategy against botulism and other toxin-mediated diseases. Expand
A Monoclonal Antibody Combination against both Serotypes A and B Botulinum Toxin Prevents Inhalational Botulism in a Guinea Pig Model
TLDR
The data suggest that a single IM administration of G03-52-01 provides pre-exposure prophylaxis against botulism from an aerosol exposure of Bo NT/A1 or BoNT/B1. Expand
Monoclonal Antibody Combinations Prevent Serotype A and Serotype B Inhalational Botulism in a Guinea Pig Model
TLDR
These mAbs are effective in preventing botulism after an aerosol challenge ofBoNT/A1 and BoNT/B1 and may represent an alternative to vaccination to prevent type A or BBotulinum neurotoxins in those at risk of BoNT exposure. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 93 REFERENCES
Botulinum Neurotoxin Vaccines: Past history and recent developments
TLDR
Research efforts have been directed at development of both improved (less local reactogenicity) botulinum toxoids and recombinant vaccines as potential vaccine candidates to replace the PBT. Expand
Recombinant Holotoxoid Vaccine against Botulism
TLDR
BoNT/ARYM represents a viable vaccine candidate for a holotoxoid against botulism and elicited an immune response against the light-chain and heavy-chain components of the toxin. Expand
Botulism and vaccines for its prevention.
TLDR
Vaccines have been and will continue to be an important line of defense for those who work with the toxin (at-risk workers) and a select population of the military, law enforcement, and first responders. Expand
Subunit Vaccine against the Seven Serotypes of Botulism
TLDR
A solid-phase assay showed that the anti-hepta-serotype HCRSera inhibited the binding of HCR serotypes A and B to the ganglioside GT1b, the first step in BoNT intoxication of neurons, which is the first E. coli-derived vaccine that effectively neutralizes each of the seven BoNT serotypes. Expand
Trivalent Vaccine against Botulinum Toxin Serotypes A, B, and E That Can Be Administered by the Mucosal Route
TLDR
This work demonstrated that carboxy-terminal peptides derived from each of the three serotypes were able to bind to and penetrate human epithelial barriers in vitro, and there was no cross inhibition of membrane binding and transcytosis. Expand
Recombinant C fragment of botulinum neurotoxin B serotype (rBoNTB (HC)) immune response and protection in the rhesus monkey.
  • J. Boles, M. West, +5 authors R. LeClaire
  • Biology, Medicine
  • Toxicon : official journal of the International Society on Toxinology
  • 2006
TLDR
This non-human primate study demonstrated the short- and long-term immunity afforded by the rBoNTB(H(c)) vaccine. Expand
An improved method for development of toxoid vaccines and antitoxins.
TLDR
This work describes here for the first time a simple, less time consuming, novel method for producing a non-toxic toxoid that is structurally and antigenically more similar to the native toxin. Expand
Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine.
TLDR
It is observed that pre-existing immunity to the wild-type Ad5 in the host had no significant influence on the protective efficacy of vaccination, suggesting that an adenovirus-vectored genetic vaccine is a highly efficient prophylaxis candidate against botulism. Expand
Subunit vaccine efficacy against Botulinum neurotoxin subtypes.
TLDR
Low dose vaccinations with HCR/A subtypes elicit unique IgG responses, and provides a basis to define how the host develops a neutralizing immune response to BoNT intoxication, may provide a reference for the development of pan-BoNT vaccines. Expand
Preclinical safety assessment of recombinant botulinum vaccine A/B (rBV A/B).
TLDR
The rBV A/B vaccine produced no apparent systemic or neurobehavioral toxicity and only transient mild inflammation at the injection site and supported its use in a Phase 1 clinical trial. Expand
...
1
2
3
4
5
...